Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the safety and tolerability of RO7239361 in boys with Duchenne Muscular Dystrophy with any genetic mutation.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Hoffmann-La Roche
NCT07423026 · Duchenne Muscular Dystrophy (DMD)
NCT06839469 · Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD)
NCT07037862 · Duchenne Muscular Dystrophy (DMD)
NCT07129954 · Fear of Falling, Duchenne Muscular Dystrophy (DMD), and more
NCT06925269 · Duchenne Muscular Dystrophy (DMD)
David Geffen School of Medicine at UCLA
Los Angeles, California
Stanford University
Palo Alto, California
University of Florida
Gainesville, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions